Please assess the completion status of the following clinical trial:

Trial Title: Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 or older.~2. Histologically or cytologically confirmed cholangiocarcinoma which was considered to be advanced/metastatic or surgically unresectable by the investigator through image examination.~3. Radiographically measurable disease per RECIST v 1.1~4. Documentation of FGFR2 rearrangement.~5. Documented disease progression after at least 1 line of prior systemic therapy.~6. ECOG performance status of 0\~1.~7. Life expectancy ≥12 weeks.~Exclusion Criteria:~1. Prior receipt of a selective FGFR inhibitor.~2. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).~3. Currently evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.~4. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemigatinib in patients with advanced/metastatic or surgically (Type: EXPERIMENTAL): Patients with advanced/metastatic or surgically unresectable cholangiocarcinoma

Based on this trial design, predict the completion outcome and termination type (if applicable).